Naratriptan 1 A Pharma

Naratriptan, the active ingredient in Naratriptan 1 A Pharma, is a Triptan (5-HT1B/1D receptor agonist) presented as a oral tablet for oral use. It treats acute migraine attacks in adults. GNH USA supplies Naratriptan 1 A Pharma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Naratriptan is a selective serotonin 5‑HT1B/1D receptor agonist used in the acute treatment of migraine, a neurovascular disorder characterized by severe headache and associated symptoms.

Migraine (with or without aura): provides rapid relief of headache pain, nausea, photophobia and phonophobia when taken at the onset of an attack.

Naratriptan may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea - Dizziness - Fatigue - Dry mouth - Paresthesia - Somnolence

Serious or Rare Side Effects: - Chest pain or tightness - Coronary vasospasm - Serotonin syndrome - Severe hypertension - Allergic reactions (rash, angioedema) - Cardiac arrhythmias

Before prescribing Naratriptan, clinicians should consider several safety aspects. - Cardiovascular assessment: evaluate history of coronary artery disease before use. - Concomitant serotonergic drugs: avoid combined use due to serotonin syndrome risk. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Age considerations: not established in pediatric patients; use in adults only. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Naratriptan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Ergot alkaloids: combined use may cause severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and SNRIs: may increase serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - Other triptans: additive vasoconstrictive effect. - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy.